BioSpace News Archive

Entrada Therapeutics, Inc. today announced that it has received authorization from the United Kingdom Medicines and Healthcare Products Regulatory Agency (MHRA) and Research Ethics Committee (REC) for its CTIMP (Clinical Trial of an Investigational Medicinal Product) for a Phase 1 clinical trial in healthy volunteers for ENTR-601-44.

Hospital for Special Surgery, has been ranked the No. 1 hospital in the nation for orthopedics for the 14th consecutive year, and advanced to No. 2 for rheumatology, in the U.S. News & World Report 2023-2024 Best Hospitals: Specialty Rankings©* analysis.

According to plan and as previously announced, Henrik Blomquist will step down as Chairman of the Board of Vitrolife AB and the Board of Directors has appointed Jón Sigurdsson as the Chairman of the Board with effect from when Bronwyn Brophy assumes the position as CEO.

Mainz Biomed NV announced that London-based Marylebone Laboratory has introduced ColoAlert®, Mainz Biomed’s flagship product, a highly effective and user-friendly at-home detection test for colorectal cancer - to its extensive UK and international customer base.

MannKind Corporation announced that its Chief Executive Officer, Michael Castagna, PharmD, will participate in one-on-one meetings at the 2023 Wedbush PacGrow Healthcare Conference on Tuesday, August 8, 2023 at the Lotte Palace in New York City.

Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced the U.S Food and Drug Administration (FDA) has cleared the QuikClot Control+ ™ Hemostatic Device to include mild and moderate bleeding in cardiac surgical procedures and bone surface bleeding following a sternotomy.

Pfizer Inc. reported financial results for the second quarter of 2023.

Zimmer Biomet Holdings, Inc. reported financial results for the quarter ended June 30, 2023.

ADC Therapeutics SA (NYSE: ADCT) today announced that it will host a conference call and live webcast on Tuesday, August 8, 2023 at 8:30 a.m. EDT to report financial results for the second quarter 2023 and provide business updates.

ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies, and Laboratoires Théa, the leading independent eye care group in Europe (“Théa”), today announced an agreement in which ProQR will divest its late stage ophthalmic assets, sepofarsen and ultevursen, to Théa.